Alnylam Pharmaceuticals Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2021 and reviewed recent business highlights. 2021 was another remarkable year at Alnylam, in which we delivered significant product revenue growth of 83% compared to 2020, achieving results at the upper end of our combined product sales guidance range driven by strong pa

The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.

Alnylam Pharmaceuticals' (ALNY) CEO Yvonne Greenstreet on Q4 2021 Results - Earnings Call Transcript

Alnylam Pharmaceuticals Inc's  ALNY Q4 product revenues increased 76% Y/Y to $198.5 million, primarily due to the continued global expansion of Onpattro and Givlaari, and sales from a third commerci

Alnylam (ALNY) delivered earnings and revenue surprises of -46.94% and 8.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to announce Q4 earnings results on Thursday, February 10th, before market open.The consensus EPS Estimate is -$1.26 (+21.3% Y/Y) and…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually, on Thursday, February 17, 2022 at 10:00 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.

Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and

Alnylam reported positive 18-month results using its drug vutrisiran for the treatment of patients with ATTR with polyneuropathy. A PDUFA date is set for April 14, 2022, for the potential approval of

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY ) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-mediated (ATTR) amyloidosis. Transthyretin amyloidosis is characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body''s organs and tissues. The details follow topline data announced Full story available on Benzinga.com

Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced detailed data from HELIOS-A Phase 3 study of vutrisiran at 18 months in patients with transthyretin-mediated (ATTR) amyloidosis. Transthyret

The shares of Alnylam Pharmaceuticals <> have bounced back from nearly an eight-month low on Wednesday after H.C